Brief: NuCana Says Data From Phase Ib Study Of Acelarin Plus Cisplatin To Treat Advanced Biliary Tract Cancer Published Online

NuCana

30/11/2020 21:07

Nov 30 (Reuters) - NuCana PLC  NCNA.O :
    * FINAL DATA FROM THE PHASE IB STUDY OF ACELARIN PLUS
CISPLATIN IN
PATIENTS WITH ADVANCED BILIARY TRACT CANCER PUBLISHED ONLINE
AHEAD OF PRINT IN THE ONCOLOGIST
    * NUCANA PLC - ACELARIN PLUS CISPLATIN'S HIGH OBJECTIVE
RESPONSE
RATE AND FAVORABLE SAFETY PROFILE CONFIRMED
    * NUCANA PLC - REMAIN ON TRACK TO ENROLL REQUIRED NUMBER OF
PATIENTS IN NUTIDE:121 BY END OF 2021

Source text for Eikon:  ID:nGNE7st6xC 
Further company coverage:  NCNA.O 

 ((Reuters.Briefs@thomsonreuters.com;))